DUBLIN, May 22, 2016 /PRNewswire/ -- Allergan plc
(NYSE: AGN) today launched IBSDonTract.com, an online resource for
those living with irritable bowel syndrome with diarrhea (IBS-D).
IBS-D, which affects approximately 15 million adults in the U.S.,
is a functional bowel disorder commonly characterized by chronic
abdominal pain and frequent diarrhea. The new website is a part of
Allergan's continued efforts to help educate the public and
patients about IBS-D, and includes key information about symptoms,
condition management and tips on speaking with a healthcare
provider about IBS-D.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
"IBS-D can have a significant impact on patients' daily lives –
but in many cases, due to embarrassment or uncertainty about
symptoms, patients wait years before seeing a doctor," said
Gavin Corcoran, MD, FACP, Chief
Medical Officer, Allergan. "IBSDonTract.com is an important
resource for patients seeking to better understand the condition
and their options. It also helps to explain why talking to their
healthcare provider sooner rather than later is critically
important, in order to shorten the time between symptom onset and
effective disease management."
According to findings from the American Gastroenterological
Association's (AGA) "IBS in America Survey," the most comprehensive
IBS survey ever conducted, polling more than 3,200 sufferers and
300 physicians, 66 percent of patients suffer with symptoms for
more than a year before talking with a doctor and 11 percent of
patients wait a decade or more before seeking medical help.
IBSDonTract.com features information that can help
patients have a more productive conversation with their healthcare
provider, including resources such as a symptom tracker,
self-assessment tool and doctor discussion guide.
For more information about IBS-D and tools for management and
treatment, please visit https://www.IBSDonTract.com/.
About IBS-D
Irritable bowel syndrome with diarrhea (IBS-D) is a functional
bowel disorder characterized by chronic abdominal pain and frequent
diarrhea, which affects approximately 15 million patients in the
U.S. Although the exact cause of IBS-D is not known, symptoms
are thought to result from a disturbance in the way the
gastrointestinal tract and nervous system interact.
IBS-D can be debilitating and there are limited therapeutic
options for managing the chronic symptoms. IBS-D is associated with
economic burden in direct medical costs and indirect social costs
such as absenteeism and lost productivity, along with decreased
quality of life.
About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin,
Ireland, is a unique, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing innovative branded
pharmaceuticals and biologic products for patients around the
world.
Allergan markets a portfolio of best-in-class products that
provide valuable treatments for the central nervous system, eye
care, medical aesthetics, gastroenterology, women's health,
urology, cardiovascular and anti-infective therapeutic categories,
and operates the world's third-largest global generics business,
providing patients around the globe with increased access to
affordable, high-quality medicines. Allergan is an
industry leader in research and development, with one of the
broadest development pipelines in the pharmaceutical industry and a
leading position in the submission of generic product applications
globally.
With commercial operations in approximately 100
countries, Allergan is committed to working with
physicians, healthcare providers and patients to deliver innovative
and meaningful treatments that help people around the world live
longer, healthier lives.
For more information, visit Allergan's website
at www.allergan.com.
Forward-Looking Statement
Statements contained in this
press release that refer to future events or other non-historical
facts are forward-looking statements that reflect
Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements. Actual
results may differ materially from Allergan's current
expectations depending upon a number of factors
affecting Allergan's business. These factors include,
among others, the risks associated with acquisition transactions;
the difficulty of predicting the timing or outcome of FDA
approvals or actions, if any; the impact of competitive products
and pricing; market acceptance of and continued demand
for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed
in Allergan's periodic public filings with
the Securities and Exchange Commission, including but not
limited to Allergan's Quarterly Report on Form 10-Q for
the quarter ended March 31, 2016 (such periodic public
filings having been filed under the "Actavis plc" name) and from
time to time in Allergan's other investor communications
. Except as expressly required by law, Allergan disclaims
any intent or obligation to update these forward-looking
statements.
CONTACTS: Media
Mark Marmur
(862) 261 7558
Frances DeSena
(973) 517 3132
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-launches-ibs-d-on-tract-new-online-resource-to-support-patients-with-irritable-bowel-syndrome-with-diarrhea-ibs-d-300272732.html
SOURCE Allergan plc